ArticleScientific reports2025
Hypermethylation of microRNA-34c CpG Island predicts unfavorable prognosis in acute myeloid leukemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The expression of microRNAs is regulated by CpG island hypermethylation in acute myeloid leukemia (AML). MiR-34c CpG island methylation status and miR-34c expression were tested in 205 de novo AML patients and 51 healthy controls. MiR-34c-mimics were transfected into THP-1 cells lines. Then Cell viability after transfection and apoptosis were detected. Western blot was used to detected the protein expression of p53. We found the down-regulation of miR-34c was associated with hypermethylation of the neighboring CpG island, and decitabine treatment rapidly restored miR-34c expression. Hypermethylation of the miR-34c CpG island was frequently observed in primary AML patients' bone marrow but not in healthy donors'. Hypermethylation of the miR-34c CpG island correlated with shorter overall survival and was further confirmed by multivariate analyses. AML patients who received decitabine and achieved complete remission, methylation of miR-34c CpG island significantly decreased and expression of miR-34c significantly increased. MiR-34c CpG island hypermethylation group was positively associated with the presence of P53 and TET2 mutations but inversely correlated with CEBPA. MiR-34c CpG island regulates miR-34c expression and hypermethylation of miR-34c CpG island is frequent in AML. There is positive feedback exists between miR-34c demethylation and p53 protein expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.